Last €36.34 EUR
Change Today +0.015 / 0.04%
Volume 170.0
GS7A On Other Exchanges
New York
As of 9:45 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GS7A) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - €41.50
52 Week Low
08/11/14 - €33.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

glaxosmithkline plc-spon adr (GS7A) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc-spon adr (GS7A) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GS7A) Key Developments

GlaxoSmithKline plc Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-19-2014

GlaxoSmithKline plc Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-19-2014 . Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom. Speakers: Simon Dingemans, Chief Financial Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee.

GIaxoSmithKline plc Announces Board Changes

GIaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015. He will succeed Sir Christopher Gent as Non-Executive Chairman with effect from 1 September 2015, or at an earlier date if released from other commitments. Sir Philip has been Chairman of The Royal Bank of Scotland Group plc (RBS) since February 2009.

China Court Fines GlaxoSmithKline $492 Million for Bribery

GlaxoSmithKline was fined $492 million for bribing doctors in China. The court sentenced the company's former China manager, Briton Mark Reilly, and four Chinese co-defendants to prison but postponed the sentences for two to four years, suggesting they may never be served. The court said it granted leniency because the defendants confessed. The case, first publicized in mid-2013, highlighted the widespread use of payments to doctors and hospitals by sellers of drugs and medical equipment in a poorly funded health system that Chinese leaders have promised to improve. Glaxo said it would pay the fine and had made changes in its business to remedy flaws cited by Chinese authorities. It said it would change the incentive system for employees and reduce its engagement with health professionals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7A:GR €36.34 EUR +0.015

GS7A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $141.36 USD -0.83
AbbVie Inc $57.87 USD -0.65
Amgen Inc $140.09 USD +0.02
Bayer AG €110.71 EUR +1.55
Novo Nordisk A/S kr282.00 DKK -2.00
View Industry Companies

Industry Analysis


Industry Average

Valuation GS7A Industry Range
Price/Earnings 13.9x
Price/Sales 2.6x
Price/Book 10.6x
Price/Cash Flow 13.8x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at